1/12
08:00 am
cogt
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Low
Report
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
1/11
03:21 pm
cogt
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]
Low
Report
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]
1/11
01:26 am
cogt
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]
Low
Report
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]
1/9
06:10 am
cogt
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/6
08:11 am
cogt
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/6
08:00 am
cogt
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
1/6
07:07 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/30
08:00 am
cogt
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Low
Report
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
12/28
10:21 am
cogt
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update [Yahoo! Finance]
Low
Report
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update [Yahoo! Finance]
12/20
01:30 am
cogt
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at
Wall Street
Low
Report
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at
Wall Street
12/19
11:38 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
12/15
06:13 pm
cogt
Cogent Biosciences: Time For A Pause [Seeking Alpha]
Low
Report
Cogent Biosciences: Time For A Pause [Seeking Alpha]
12/8
12:13 pm
cogt
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/8
11:41 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/8
07:30 am
cogt
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Low
Report
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
12/6
09:30 am
cogt
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
Medium
Report
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
11/25
01:49 pm
cogt
Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/16
11:28 am
cogt
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]
11/14
08:00 am
cogt
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Low
Report
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
11/13
08:11 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.
11/13
01:17 am
cogt
Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]
11/11
11:16 pm
cogt
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
Medium
Report
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
11/11
01:11 pm
cogt
Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial [Yahoo! Finance]
11/11
10:38 am
cogt
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside [Seeking Alpha]
Medium
Report
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside [Seeking Alpha]
11/11
08:16 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at Robert W. Baird from $14.00 to $34.00. They now have a "neutral" rating on the stock.
Medium
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at Robert W. Baird from $14.00 to $34.00. They now have a "neutral" rating on the stock.